AAM
SCLN

Azzad Asset Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Azzad Asset Management’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-10,500
Closed -$47.8K – 296
2014
Q1 		$47.8K Buy
+10,500
New +$50.7K 0.03% 256

Other funds holding SCLN

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
QBFM
QS Batterymarch Financial Management New York $3.78B AUM 22.02% 1-Year Est. Return

Azzad Asset Management's SCLN Position: Q2 2014 in Review

Azzad Asset Management sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q2 2014, closing a stake of 10,500 shares — an estimated $47.8K sold.

Azzad Asset Management first reported a position in SCLN in Q1 2014 and held it in 1 quarter. The position peaked at $47.8K in Q1 2014. 95 funds tracked by Wall St. Rank hold SCLN as of Q2 2014.

  • Azzad Asset Management reported no remaining Sciclone Pharmaceuticals Inc position as of Q2 2014 after selling out during the quarter.
  • Azzad Asset Management sold 10,500 Sciclone Pharmaceuticals Inc shares in Q2 2014, an estimated $47.8K.
  • Azzad Asset Management first reported a position in Sciclone Pharmaceuticals Inc in Q1 2014 and held it in 1 quarter.
  • Azzad Asset Management's Sciclone Pharmaceuticals Inc position peaked at $47.8K in Q1 2014.
  • 95 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q2 2014.

Based on Azzad Asset Management's 13F filing for Q2 2014, filed 3 Apr 2024.